A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer's Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase

Trial Profile

A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer's Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2015

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors Novartis
  • Most Recent Events

    • 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
    • 11 Sep 2012 Tolerability results presented at the 16th Congress of the European Federation of Neurological Societies.
    • 11 Sep 2012 Effects of treatment on the autonomy and higher level function subscales of the ADCS-IADL presented at the 16th Congress of the European Federation of Neurological Societies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top